Skip to content

Study · In vitro (cells) · 1998

10 results

Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells.

Kaliman P, Canicio J, Shepherd PR, Beeton CA, Testar X, Palacín M, Zorzano A

Molecular endocrinology (Baltimore, Md.)1 Jan 1998Cited by 87 (Europe PMC)

PMID9440811 (opens in a new tab)DOI10.1210/mend.12.1.0047 (opens in a new tab)PepBankPUB-09440811
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In L6E9 cells, des(1‑3)IGF-I induced myotube formation.

    In plain wordsIn cells, des(1‑3)IGF-I induced muscle tube formation.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMyotube formation
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.
  2. 02LabIn vitro (cells)Mechanism

    In L6E9 cells, des(1‑3)IGF-I induced myogenin gene expression.

    In plain wordsIn cells, des(1‑3)IGF-I induced myogenin gene expression.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMyogenin gene expression
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.
  3. 03LabIn vitro (cells)Mechanism

    In L6E9 cells, des(1‑3)IGF-I induced the GLUT4 glucose carrier.

    In plain wordsIn cells, des(1‑3)IGF-I induced the GLUT4 glucose carrier.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseGLUT4 induction
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

Studies that did not test the peptide alone7

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, LY294002 blocked IGF-induced myotube formation, in experiments including des(1‑3)IGF-I.

    In plain wordsIn cells, LY294002 blocked IGF-induced muscle tube formation, in experiments including des(1‑3)IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced myotube formation with LY294002
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    The addition of LY294002 to the differentiation medium totally inhibited these IGF-induced myogenic events without altering the expression of a non-muscle-specific protein, beta1-integrin.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 05LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, LY294002 blocked IGF-induced myogenin expression, in experiments including des(1‑3)IGF-I.

    In plain wordsIn cells, LY294002 blocked IGF-induced myogenin expression, in experiments including des(1‑3)IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced myogenin expression with LY294002
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    The addition of LY294002 to the differentiation medium totally inhibited these IGF-induced myogenic events without altering the expression of a non-muscle-specific protein, beta1-integrin.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  3. 06LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, LY294002 blocked IGF-induced GLUT4 induction, in experiments including des(1‑3)IGF-I.

    In plain wordsIn cells, LY294002 blocked IGF-induced GLUT4 induction, in experiments including des(1‑3)IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced GLUT4 induction with LY294002
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    The addition of LY294002 to the differentiation medium totally inhibited these IGF-induced myogenic events without altering the expression of a non-muscle-specific protein, beta1-integrin.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  4. 07LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, LY294002 did not alter beta1-integrin expression during inhibition of IGF-induced differentiation.

    In plain wordsIn cells, LY294002 did not alter beta1-integrin expression during inhibition of IGF-induced differentiation.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeBeta1-integrin expression with LY294002
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    The addition of LY294002 to the differentiation medium totally inhibited these IGF-induced myogenic events without altering the expression of a non-muscle-specific protein, beta1-integrin.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  5. 08LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, dominant negative p85 impaired IGF-induced cell fusion versus parental or wild-type p85 cells.

    In plain wordsIn cells, dominant negative p85 impaired IGF-induced cell fusion versus parental or wild-type p85 cells.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced cell fusion in delta p85 cells
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Comparator
    Parental cells or cells expressing wild-type p85
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    IGF-induced myogenic parameters in L6E9-delta p85 cells, ie. cell fusion and myogenin gene and GLUT4 expression, were severely impaired compared with parental cells or L6E9 cells expressing wild-type p85.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  6. 09LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, dominant negative p85 impaired IGF-induced myogenin expression versus parental or wild-type p85 cells.

    In plain wordsIn cells, dominant negative p85 impaired IGF-induced myogenin expression versus parental or wild-type p85 cells.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced myogenin expression in delta p85 cells
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Comparator
    Parental cells or cells expressing wild-type p85
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    IGF-induced myogenic parameters in L6E9-delta p85 cells, ie. cell fusion and myogenin gene and GLUT4 expression, were severely impaired compared with parental cells or L6E9 cells expressing wild-type p85.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  7. 10LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In L6E9 cells, dominant negative p85 impaired IGF-induced GLUT4 expression versus parental or wild-type p85 cells.

    In plain wordsIn cells, dominant negative p85 impaired IGF-induced GLUT4 expression versus parental or wild-type p85 cells.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF-induced GLUT4 expression in delta p85 cells
    Study

    n: not reported in source

    L6E9 skeletal muscle cells
    Comparator
    Parental cells or cells expressing wild-type p85
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    IGF-induced myogenic parameters in L6E9-delta p85 cells, ie. cell fusion and myogenin gene and GLUT4 expression, were severely impaired compared with parental cells or L6E9 cells expressing wild-type p85.
    1 context sentence
    Summary · context
    IGF-I, des(1-3)IGF-I, or IGF-II induced L6E9 skeletal muscle cell differentiation as measured by myotube formation, myogenin gene expression, and GLUT4 glucose carrier induction.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.